@article{580eb4d8fbd940bdbd5b2993b5572a4c,
title = "Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study",
abstract = "Background Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.Methods With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 ml/min, weightResults Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.Conclusion There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.",
keywords = "anticoagulants, clinical trial, haemorrhage, k oral anticoagulants, management, off-label use, phase iv, routine clinical-practice, stroke, thromboembolism, trends, warfarin, Anticoagulants, Stroke, MANAGEMENT, phase IV, TRENDS, ROUTINE CLINICAL-PRACTICE, Off-label use, WARFARIN, Clinical trial, Haemorrhage, Thromboembolism, K ORAL ANTICOAGULANTS",
author = "{de Vries}, T.A.C. and M.E.W. Hemels and F. Cools and H.J.G.M. Crijns and L. Yperzeele and P. Vanacker and I. Blankoff and P. Lancellotti and G.H. Mairesse and {de Veer}, A. and R.C. Arroyo and E. Catez and {de Pauw}, M. and T. Vanassche and {de Asmundis}, C. and P. Kirchhof and {De Caterina}, R. and {de Groot}, J.R. and {ETNA-AF-Europe principal investigators from Belgium and the Netherlands}",
note = "Funding Information: T.A.C. de Vries reports having received compensation for travel and accommodation expenses from Daiichi Sankyo. His primary institute (Department of Cardiology Rijnstate) has received a grant for an unrelated project from Boston Scientific. M.E.W. Hemels reports speaker fees from BMS/Pfizer, Daiichi Sankyo, Bayer, Boehringer Ingelheim, and a research grant from the Netherlands Federation of Anticoagulation clinics. F. Cools reports consultancy fees from Bayer and Daiichi Sankyo. L. Yperzeele reports speaker fees from Pfizer and Daiichi Sankyo, and consultancy honoraria from Boehringer Ingelheim and Daiichi Sankyo. A. de Veer reports consulting fees from Bayer and Boehringer Ingelheim. T. Vanassche has served as a consultant and/or has participated on advisory boards for Daiichi Sankyo, Boehringer Ingelheim, Bayer, BMS/Pfizer, Sanofi, and Leo Pharma. C. de Asmundis has received compensation from teaching purposes and proctoring from AF Solutions, Medtronic, St Jude Medical, Biotronik, and is a member of the steering committee of the ETNA-AF-Europe study. P. Kirchhof receives research support for basic, translational, and clinical research projects from the European Union (BigData@Heart; grant agreement EU IMI 116074), the British Heart Foundation (PG/17/30/32961; AA/18/2/34218), the Leducq Foundation, the Medical Research Council (UK), and the German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past. He is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). R. De Caterina is a co-author of the ESC Guidelines on Atrial Fibrillation 2010–2012, APPRAISE‑2, ARISTOTLE, AVERROES, ENGAGE-AF-TIMI 48, and Re-DUAL PCI. He is also a steering committee member of the ETNA-AF-Europe study, and the national coordinator for Italy. He reports having received fees, honoraria and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, Novartis, Merck, Portola, and Roche. J.R. de Groot is supported by a personal grant from NWO ZonMW 016.146.310 and reports research grants to his institution from AtriCure, Boston Scientific, Medtronic and Abbott, and consultancy/speaker fees from AtriCure, Bayer, Daiichi Sankyo, Novartis, Medtronic, and Servier. H.J.G.M. Crijns, P. Vanacker, I. Blankoff, P. Lancellotti, G.H. Mairesse, R. Casado Arroyo, E. Catez and M. de Pauw declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2021",
month = mar,
day = "1",
doi = "10.1007/s12471-020-01518-7",
language = "English",
volume = "29",
pages = "158--167",
journal = "Netherlands Heart Journal",
issn = "1568-5888",
publisher = "Bohn Stafleu van Loghum",
number = "3",
}